  |
 |
It's an ugly truth about medicine: Many common ailments, like acne, can only be treated, not cured. That's good news for a company like Bradley Pharmaceuticals, which markets niche dermatology and gastrointestinal medications. Why FORTUNE likes it: Has new drugs and new patents for ailments that don't go away. See more from Fortune.com. |
| ||||
| Market value | 356 million | |
P/E (2005) |
13.3 |
|
|
|||
| Total Return (Year to date) |
-10.3% | P/E (5 yr. Avg.) |
21.7 | |
|
|
|||
| Earnings Gr. Rate (past 5 years) |
120.0% | Return on equity | 20.9% | |
|
|
|||
| Revenue Gr. Rate (past 5 years) |
51.0% | Net profit margin | 23.9% | |
|
|
|||
| Earnings Gr. Rate (next 3-5 years) |
22.0% | Net Profit margin (5 yr. Avg.) |
9.5% | |
| ||||
| Source: Thomson/Baseline | ||||
 |
Bradley Pharmaceuticals |
 |
Symantec |
 |
Electronic Arts |
 |
Thor Industries |
 |
Encore Acquisition |
 |
Two more to bet on from Fortune.com |